The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
But launch is unlikely before 2024.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.